Live feed07:26:23·948dNEWSReleasevia Quantisnow+2AstraZeneca's $2.4B Fusion Pharmaceuticals' Acquisition Signals Shift In Efforts From Traditional Regimens For More Targeted Cancer TreatmentsByQuantisnow·Wall Street's wire, on your screen.AZNAstraZeneca PLCBMYBristol-Myers Squibb CompanyFUSNFusion Pharmaceuticals Inc.LLYEli Lilly and CompanyRYZBRayzeBio Inc.Health Care
